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INTRODUCTION 
  Periodontitis is a multifactorial disease that is characterised by chronic 
inflammation of the supporting tissues of the tooth. Although the 
etiopathogenesis of periodontal disease is not yet fully understood, evidence 
indicates that periodontitis results from an exaggerated, non-protective host 
immune response to microorganisms that are present in a sub-gingival 
biofilm
88
. The loss of periodontal ligament fibres and alveolar bone is thought 
to be a result of host derived cytokines and proteases rather than bacterial 
derived factors. 
  Consequently pro inflammatory cytokines like IL-1β, IL-6, TNF-α and 
host derived proteases like MMP 8 and 9 have been implicated in the disease 
process and used as biomarkers to predict disease progression
65
.  Host derived 
breakdown products used as biomarkers are proteins that contribute to the 
homeostasis of the periodontium under physiological conditions and are 
released and/or undergo alterations in inflamed states.  
  Basic fibroblast growth factor (FGF2) originally identified as a protein 
capable of promoting fibroblast proliferation, plays an important role in 
endothelial cell proliferation, migration, differentiation, and survival
38
. As 
both collagen turn over and neovascularisation are key events, it may be 
expected that bFGF plays an important role in the homeostasis of the 
periodontium. Periodontitis being a chronic inflammation that is associated 
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with collagenolysis, it is reasonable to assume that bFGF is involved in the 
pathogenic process as well. 
  The role of tobacco as a risk factor in periodontal disease has been well 
documented. Voluminous literature exists regarding its ability to increase the 
extent and severity of periodontal disease, affect healing and worsen the 
prognosis of chronic periodontitis
10
. Several mechanisms have been proposed 
to explain its role in the etiopathogenesis of periodontal disease, including its 
influence on the microvasculature and fibroblast microtubular assembly.  
  Tobacco chewing is a habit that is fairly prevalent in many Asian 
countries including India
2,3
. Various constituents of smokeless tobacco like 
nicotine, nitrosamide have been demonstrated not only to have carcinogenic 
potential but also induce inflammatory changes in the oral mucosa.  The 
effects of tobacco chewing on the periodontium have not been studied as 
extensively as that of smoking, but several studies have reported increased 
gingival recession and attachment loss as a result of tobacco chewing
13
. 
  Based on its ability to influence vascularity and to induce fibrosis, it is 
plausible that some of the effects of tobacco chewing on periodontal disease 
are mediated through bFGF. 
  The advantages of using saliva over GCF for identifying biomarkers of 
interest include ease of collection, non-invasiveness and potential for rapid 
screening
64
.  As the flow rate of saliva is not affected by tobacco chewing, it 
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may be used as the diagnostic medium to predict progressive periodontal 
disease. 
  bFGF and FGFR have been previously identified in saliva and used as 
markers in oral malignancy. However, its role as a potential salivary 
biomarker in the etiopathogenesis of periodontitis in a tobacco chewing 
population is yet to be investigated.
14,15 
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AIMS AND OBJECTIVES 
 The aims of the present study were: 
1. To identify and quantify the level of bFGF in saliva of patients with 
chronic periodontitis with tobacco chewing habit 
2. To compare the salivary bFGF levels in periodontal health with that of 
chronic periodontitis patients with tobacco chewing habit  
                              
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature  
Review of Literature 
 
 
 
 
5 
 
REVIEW OF LITERATURE 
Periodontitis is defined as an inflammatory disease of the supporting 
tissues of the teeth caused by specific microorganisms resulting in progressive 
destruction of the periodontal ligament and alveolar bone with pocket 
formation, recession or both. 
The chronic activity of periodontal diseases progress with cyclic period 
of exacerbation and remission. The attachment loss associated with 
periodontitis has been seen either continuously or in episodic bursts of disease 
activity. 
Microbial challenge: 
The plaque formation begins with gram positive bacteria which 
accumulate on the tooth surface and if they continue to grow it results in an 
environment that favours growth of gram negative bacteria. A non-protective 
host response further facilitates bacterial colonisation and growth. 
Predominant bacterial species that have been involved in the disease process 
include P.gingivalis, A.actinomycetamcomitans, T.denticola, B.forythis, 
F.nucleatum, P.intermedia, C.rectus, Peptostreptococcus, E.corrodens.
21 
Host response to the microbial challenge: 
Bacteria and bacterial products interact with the junctional epithelium 
and penetrate the underlying connective tissue. The small blood vessels plexus 
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seen beneath but deep to the junctional epithelium becomes inflamed. 
Leucocytes exit the post capillary vessels and there is a large increase in the 
neutrophil count, as it moves through the Junctional epithelium and into the 
sulcus. 
The bacterial normal metabolic products including fatty acids and the 
peptide N-formylmethionylleucylphenyalanine and LPS of gram negative 
bacteria, these products activate the junctional epithelial cells to release 
various inflammatory mediators including IL-8,IL-1α,PGE2 ,MMP-2, MMP 
and TNF-α. 
           The tissue response to the early signal by widening of intercellular 
spaces and found first fluid filling space which some as a medium for 
diffusion and neutrophil migration.
20 
          The inflammatory phase involves a reactive defensins response to the 
bacterial products. This evidence by the activation of serum proteins into the 
tissue movement of neutrophil out of the vessels and into the sulcus, epithelial 
cells proliferation and selective deposition of mononuclear cells in the 
tissues.
23 
       This shapes the local and systemic immune responses. There is an 
increase in tissue lymphocytes, plasma cells and macrophages which changes 
the metabolism of the local fibroblasts to favor a reduction in collagen 
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synthesis and activation of the local and systemic immune responses and 
production of antibodies. 
Biomarker: The term „biomarker‟ refers to biologic substances that can 
be measured and evaluated to serve as indicators of biological health, 
pathogenic processes, environmental exposure and pharmacologic responses 
to a therapeutic intervention.
29 
Salivary biomarkers in periodontitis: 
MMP -8, OPG, MIP-1α, IL -1β, IL – 8 and TNF -1α were reported to 
be associated with chronic periodontitis. 
            MMP -8 was reported to be a biomarker indicative of response to 
therapy (Sexton).
87 
AST and P.gingivalis demonstrated high levels of predictive ability for 
disease progression.  
A novel diagnostic approach was investigated for the combinatorial 
ability of P.gingivalis, IL -1 β and MMP-8 to detect periodontitis. 
Fine DH performed a longitudinal evaluation of salivary cytokines in 
children who developed localized aggressive periodontitis and reported MIP-
1α as an early detection marker.29 
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The peptide, Procalcitonin is an established serum biomarker for 
inflammation. Increased mean levels of salivary procalcitonin were found for 
subject with periodontitis compared with healthy control subjects (Bassim 
CW). 
Point –of care diagnostics: 
In the absence of one specific biomarker for periodontal diseases, a 
panel of markers identified through longitudinal analysis may be employed 
using a lab on chip technology. This technology allows rapid screening of 
large population and allows results to be obtained immediately.  
Personalized medicine in periodontics: 
Personalized medicine is a medical model that uses genetic, genomic, 
environmental and clinical diagnostic testing to individualize patient care. This 
approach uses clinical assessment and subclinical profiles to improve highly 
individualized diagnosis, prognosis and treatment algorithm (Giannobile)
33 
Personalized medicine  for periodontal diseases may soon involve 
utilization of saliva to develop subclinical  profiles  ,identifying and measuring 
specific genotypes  putative  pathogen inflammatory marker and collagen 
degradation biomarkers to make  informed  clinical  decisions about disease  
susceptibility, site specific –risk and treatment intervention (Kornman KS) . 
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During the screening phase, the use of saliva to recognize patients at 
risk for future disease activity makes it possible to employ risk management 
strategies, preventive care and/or behavior change on the part of the patient to 
prevent the onset of the disease at the diagnostics stage, identifying the 
presence of disease at the earliest possible stage may allow for less-invasive 
treatment. (Taba M)
98 
Smokeless tobacco: 
Smokeless tobacco is tobacco that is not burned. It is also known as 
chewing tobacco, oral tobacco, spit or spitting tobacco, dip, chew and snuff. 
most people  chew or  suck  (dip)  the tobacco  in their mouth and spit  out the 
tobacco juices  that build up  ,although  “spitless” smokeless tobacco  has been  
developed. Nicotine in the tobacco is absorbed through the lining of the 
mouth. 
People in many regions and countries including North America, 
Northern Europe, India and other Asian countries and some parts of Africa 
have a long history of using Smokeless tobacco products.
70  
There are two main types of smokeless tobacco:
 
Chewing tobacco which is available as loose leaves plugs (bricks) or 
twists of ropes, a piece of tobacco is placed between cheek and lower lip, 
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typically toward the back of the mouth. It is either chewed or held in place. 
Saliva is spit or swallowed. 
Snuff, which is finely cut or powered tobacco, may be sold in different 
scents and flavours
82
. It is stored moist or dry. It is available loose in 
dissolvable lozenges or Strips or in small pouches similar to tea bags .the user 
places a pinch of moist snuff between the cheek and gums or behind the upper 
or lower lip. Another name for moist Snuff is sinus (pronounced “snooze”). 
Some people inhale dry snuff into the nose. 
Harmful chemicals in smokeless tobacco: 
            There is no safer form of tobacco, at least 28 chemicals in smokeless 
tobacco have been found to cause cancer.
50
 The most  harmful chemicals  in 
smokeless tobacco  are tobacco specific, nitrosomine  which are formed during  
the growing ,curing  ,fermenting  and aging of tobacco  .the level of tobacco  -
specific  nitrosomines  varies  by product.
105 
             In addition to a variety of Nitrosomines, other cancer causing 
substances. tobacco include  polonium-210 (a radioactive element found in 
tobacco fertilizer) and  polynuclear  aromatic hydrocarbons  (also known as  
polycyclic  aromatic hydrocarbon).
49 
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Clinical effects of smokeless tobacco: 
Oral mucosal disease: 
Tobacco use   is associated with a range of changes  to the oral mucous 
membrane  cells. Oral candidiasis is a mucosal infection caused by the candida 
albicans fungus.
1
It has been suggested that tobacco use may slow the immune 
system, making smokeless tobacco users more susceptible to infections. 
Leukoplakia: 
Oral leukoplakia is the most common form of potentially malignant 
disorder in the oral cavity .
104
 it is estimated that three out of every four users 
of smokeless tobacco will develop an Oral leukoplakia at the site where they 
place   the tobacco product in their mouth
96
. A case control study of smokeless 
tobacco use amongst South Asians also found a significantly increased risk of 
esophageal cancer associated with the use of areca nut and betel Quid when 
used with chewing tobacco.
77 
Wound Healing: 
       Tobacco use is known to impair wound healing. Tobacco chewers have 
decreased level of   salivary and serum Immunoglobulin which affects   wound 
healing in the oral cavity and mouth‟s ability to clear pathogens 81. 
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Tobacco chewers have decreased levels of blood oxygenation leading 
to decreased oxygen delivery to the tissues.
95
 Loss of blood clot that follows 
the removal of teeth occurs four times more frequently in smokers than non-
smokers.
22 
A significantly higher prevalence of bleeding on probing was found in 
betel quid chewers than non-chewers among the subjects with higher plaque 
level, greater gingival inflammation, deeper probing depth or greater 
attachment loss.
103
  
Betel chewing has been associated with an increased gingival bleeding 
and an increased prevalence of Aggregatibacter actinomycetemcomitans and 
Porphyromonas gingivalis as determined by PCR. Also an increased 
periodontal progression due to betel chewing has been suggested. 
Ling et al reported higher levels of A. actinomycetemcomitans and 
P.gingivalis in betel chewers using a sensitive but non-quantitative PCR 
method. The prevalence of the periodontitis associated bacteria observed using 
the lower detection level of score 1 (>104 ) was close to 100% in both chewers 
and non-chewers for all bacteria tested, while the significant differences were 
found using the higher cut off level (score 3 or higher corresponding to >105 ).  
Studies also reported that periodontitis among the betel chewers was 
more severe than in non-chewers indicated by both higher mean values of 
probing pocket depth and attachment loss. 
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SMOKELESS TOBACCO AND PERIODONTAL DISEASE: 
Smokeless Tobacco (ST) contains numerous chemicals, such as 
nicotine and nitrosamines, which are potential local irritants. Although ST 
products vary considerably in their composition, nicotine is a common 
element in all of these products. Plasma levels in ST users and smokers range 
from 22 to 73 ng/ml and salivary concentrations range from 70 to 1560 μg/ml. 
27·28. Irritation from ST components may stimulate the production of 
inflammatory mediators, thereby leading to the observed tissue alterations 
seen in ST users. 
Robertson et al could not find a relationship between poor oral hygiene 
and gingivitis in the development of oral ST lesions. They hypothesized that 
localized tissue destruction following ST usage may be due, in part, to 
production of inflammatory mediators, such as PGE2 and IL-lß, in response to 
ST alone or in combination with bacterial lipopolysaccharide (LPS). Because 
monocytes are the primary target cell for LPS, which is ubiquitous in the 
periodontium, and major producers of periodontal inflammatory mediators, 
PGE2 and IL- ß.  
Their study revealed that smokeless tobacco is capable of stimulating 
monocyte secretion of PGE2 and IL-lß. Smokeless tobacco was a more potent 
stimulator of PGE2 than P.gingivalis LPS and had an effect similar to E. coli 
LPS. Even though monocytes/macrophages represent only 3.5% of total cell 
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counts in progressing Periodontitis sites, 25 these cells are capable of 
producing large amounts of PGE2 and IL-lß. 
Studies have established that the macrophage/fibroblast volume 
density ratios are elevated in habitual ST lesions compared to non-placement 
sites in the same individual. Elevated secretion of PGE2 and IL-lß has been 
associated with active periodontitis and is likely to be involved in the localized 
soft tissue destruction seen at the site of ST placement.  
In view of IL-1‟s role in keratinocyte proliferation and its 
inflammatory effects, this cytokine may contribute to mucosal and gingival 
alterations observed in ST users. 
ST placement sites exhibit higher levels of gingival inflammation 
accompanied by an increase in gingival crevicular fluid (GCF) levels of 
inflammatory mediators Prostaglandin E2 (PGE2) and interleukin-1 (IL-1). 
Prostaglandin E2 and IL-1 have been directly linked to increased epithelial 
proliferation in other conditions, as well as to collagen and alveolar bone loss 
in periodontal diseases. Therefore, these are potential mediators involved in 
ST induced mucosal changes. 
The tissue destruction in periodontal disease mainly results from 
various host-derived pro-inflammatory mediators, such as interleukin-1, TNF-
a, and PGE2.42. ANE significantly increases the production of PGE2 through 
the activation of COX-2 expression in human PMNs. 
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In addition, the intracellular calcium levels and p38 and ERK MAPK 
signalling pathways are involved in the ANE-induced PGE2 synthesis. These 
findings indicate that the activation of the COX-2/PGE2 pathway may be one 
of the mechanisms by which the areca nut augments the periodontal 
destruction in areca quid chewers. 
Areca nut extracts increased the levels of IL-1β, IL-6, IL-8, and tumor 
necrosis factor - alpha (TNF-α), which are responsible for amplifying the 
inflammatory response in periodontal tissues. IL-1β and IL-8 production and 
secretion are increased when cells come in contact with nicotine.  
In addition, the areca nut, which contains arecoline and nicotine, 
inhibits the growth and attachment of fibroblasts, inhibits protein synthesis, 
suppresses the differentiation and functionality of dendritic cells, and might be 
cytotoxic for periodontal fibroblasts, leading to the progression of the pre-
existing periodontal disease and impairment of the periodontal attachment. 
Buccal sites usually exhibit a thin alveolar bone causing alveolar 
dehiscence, and that tobacco chewing is likely to cause chemical injury to the 
thin gingiva, leading to the loss of marginal gingiva. Like RC, the CAL was 
significantly higher in gutka chewers. Javed et al, revealed site-specific 
gingival inflammation at the area of placement. 
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SMOKELESS TOBACCO AND CLINICAL EFFECTS ON THE 
PERIODONTIUM: 
Epithelial proliferation and down-growth along the root, as well as 
collagen and bone destruction, are the major structural changes evident in 
periodontal attachment loss and gingival recession. (Baker DL et al). Increased 
epithelial thickness is the primary alteration in the ST-induced white lesion, 
although sub-epithelial inflammation and salivary fibrosis also are present. 
These changes occur in response to the chemical and/or mechanical irritating 
effects of ST components. This stimulus is likely to result in the release of 
inflammatory mediators which may play a role in the development of 
pathologic alterations. 
The higher codes of loss of attachment were observed in pan chewers 
with tobacco compared with pan chewers without tobacco. It was found that 
pan chewers with tobacco had 7 times more risk of having loss of attachment 
when compared with the pan chewers without tobacco, emphasizing the fact 
that although betel nut has deleterious effects on the periodontium, the 
addition of tobacco leads to a synergistic effect between betel nut and tobacco 
on the periodontal tissues. 
Kumar et al had shown a significant impact on the severity of 
periodontal diseases among tobacco users as compared to non-users and the 
Review of Literature 
 
 
 
 
17 
 
risk of periodontal pockets increased as the duration and frequency of tobacco 
consumption increased. 
Sood et al also revealed higher prevalence of periodontal disease in 
different smokeless tobacco users. Peak incidence of smokeless tobacco 
consumption was observed in the age group between 21 and 30 years (39.4%) 
in this study. Increasing demand and usage amongst young adults and in older 
women living in rural southern areas in United States have been reported by 
many.  
Greater gingival inflammation was seen in smokeless tobacco users 
and alone smokeless tobacco users than non-tobacco users. Attachment loss is 
an important component of the periodontal disease measure that defines past 
history of the disease and is especially pertinent in the assessment of current 
exposure to tobacco. Present study revealed CAL of more than 5 mm in 
majority of smokeless tobacco users. 
ST users tend to have more severe recession (REC) and Clinical 
Attachment Loss (CAL) and a greater proportion of sites with higher values of 
REC and CAL compared with never users. The greatest increase in severity of 
CAL was found to be localized to sites on mandibular teeth, buccal surfaces, 
anterior and molars, which may be a result of the retention of the ST product 
in the oral cavity. 
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Some in vitro studies have shown that areca nut extracts and nicotine 
suppress the growth of periodontal fibroblast and gingival keratinocytes. 
Although clinical studies have investigated the influence of habitual Betel 
Quid (BQ) chewing on periodontal health, the difference in the severity of 
periodontal disease among individuals chewing BQ with and without tobacco 
remains unclear. It is therefore hypothesized that individuals chewing BQ with 
tobacco experience more intense periodontal inflammation as compared with 
those chewing BQ without tobacco.  
BOP was significantly higher among individuals chewing BQ with 
tobacco as compared with those chewing BQ without tobacco. Habitual 
tobacco smoking and alcohol consumption are independent risk factors for 
periodontal inflammation. 
Biology of fibroblast growth factor: 
Fibroblast growth factor which was first discovered in pituitary 
extracts in 1973 is broadly expressed in cells and tissues. Acidic  fibroblast 
growth factor (FGF1) and basic  fibroblast growth factor 2 (FGF2) were 
originally isolated from the brain and pituitary gland  as growth factors for 
fibroblast ,since then  at least  22 distinct  FGF s  have been identified or 
isolated Fibroblast growth factors have been found in both vertebrates and 
invertebrates. Many  fibroblast   growth factor genes have been identified  in 
vertebrates including ten Fibroblast growth factor  in zebra fish (FGF-2-
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4,6,8,10,17a,18,24) six in xenopus (FGF 2-4,8-10) in chicken (FGF1-4,8-
10,12,13,16,18-20) in mice (FGF1-18,20-23) and humans (FGF1-14,16-
23)whereas only three drosophilia  FGF genes and two caenorrhabditis  
elegans.
45
  FGF genes  have been observed in invertebrates. Human FGFs  a 
contain 22 members  FGF1, FGF2, FGF3, FGF4(INT2), FGF5, FGF6, FGF7, 
FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, 
FGF17, FGF18, FGF19, FGF20, FGF21, FGF22 and FGF23 (Katch M)
52 
The Fibroblast growth factor family members comprises 23 members 
although there are only 18 FGFR ligands. Four family members do not bind 
with FGFR as FGFR as FGF homologous factors (FGF11, FGF12, FGF13, 
FGF14) and are more correctly referred to as FGF homologous factors.
25
 In 
addition there is no human FGF-15 gene, the gene orthologous to mouse FGF-
15 and FGF -19.
63 
Biological functions of FGFs: 
FGFs exert their physiological roles on functions such as cell 
proliferation, migration, differentiation and angiogenesis in various cells and 
tissues 
109
. 
Cell proliferation: 
Cell proliferation  by FGFs have been reported  in many cell types  
including enothelial cell FGF 1 is a proliferative factor for human or 
Review of Literature 
 
 
 
 
20 
 
adipocytes
41
 that may be important to overall  regulation of human 
adipogenesis in additionFGF1leads to   an increase in the proliferation   of  
IEC-6  Caco-and HT-29  cell lines  cell lines with FGF2 and FGF7. FGF2 
induces cell proliferation after flia specific gene transfer in mice and 
stimulates the proliferation and survival of neuro-epithelial cells isolated from 
the telencephalon and mesencephalon   of E10. FGF4 knocked mouse embryos 
experience   post implantation lethally owing to the necessity of FGF4 for 
trophoblast proliferation. FGF7 (called human KGF) is related to the epithelial 
cell growth. FGF10 play a role in the pathogenesis of prostrate cancer via 
facilitation epithelial cell proliferation (Thomson A.A).
108
 FGF18 has also 
have  been  stimulate the proliferation of cultured mouse primary osteoblast, 
osteoblastic  MC373-E1  cells, primary  chondrocytes   and prechondrocytic 
ATDC5 cells, although inhibited the differentiation and matrix synthesis of 
these cells.
40
 Interestingly some FGF s stimulate  proliferation of cancer cells 
as well as  normal cells . 
Cell migration: 
Cell migration is a central processes in the development and 
maintenance of multi cellular organisms. Tissue formation during embryonic 
development, wound healing, and immune responses all require the 
orchestrated movement of cells in particular   directions to specific locations. 
Cells often migrate    in response to and forward specific   external signals   in 
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a process and forward   specific external signals in a process known as 
chemotaxis
11
. 
Cell migration of FGF‟s varies with subfamilies, apparently both FGF1 
and FGF2 play important roles in the migration of cochlear ganglion neurons 
in mice. FGF2  induces cell migration  after flia specific gene transfer  in 
mice, and stimulates cell  migration of  mouse  embryonic limb myogenic  
cells   such as  FGF4(Webb .S)
110
. FGF7 is known to stimulate migration and 
plasminogen activity (PA) of normal human keratinocytes similar to FGF2, 
FGF8 is a potent chemoattractant in the migration of mesencephalic neural 
crest cells (Kubota Y).
113 
Cell differentiation: 
In  development  biology, cellular differentiation is the process by 
which  a less specialized  cell becomes   a more specialized  cell  type 
differentiation occurs  numerous  times  during  the development  of 
multicellular organisms  as they change   from a  single  zygote  to a complex 
system of tissues and cell types.
26
 Differentiation  is  common in adults as well   
.specifically   adult stem cells  divide  and create  fully differentiated daughter  
cells  during tissue repair  and   normal cell turnover .differentiation 
dramatically changes  the size, shape, membrane potential, metabolic activity 
and responsiveness of a cell signal.
115 
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Cell differentiation of FGF also varies with subfamilies
47
. FGF1 and 
FGF2  play important roles in the initial differentiation of cochlear  ganglion 
neurons in mice (29), moreover FGF2  stimulates the  differentiation  of  
neuro-epithelial Cells into mature   neurons and glial cells  FGF7 is essential 
for the morphogenesis of subrabasal  keratinocytes  and establishment  of the 
normal program of keratinocyte  differentiation .exogenous  FGF20  
stimulates the differentiation of  monkey stem cells  into dominogeric neurons 
after treatment  in vitro.
114 
Angiogenesis: 
Angiogenesis is the process of the formation of new blood vessels 
from pre-existing vessels. The process plays a key role in various 
physiological and pathological conditions such as embryonic development, 
wound repair, inflammation and tumor growth angiogenesis is a multistep 
process that begins with the degradation of the basement membrane by 
activated endothelial cell sprouts into the stromal space.   
Numerous indicators of angiogenesis have been identified, including 
members of the VEGF family angiopoietins, TGF –alpha and beta, PDGF 
TNF-α, interleukins, chemokines and members of fibroblast growth factor 
(FGF) family. However only a limited number of the 22 members of the FGF 
family have been investigated for their angiogenic potential in vitro and in 
vivo.
9
 the angiogenic properties of FGF1 and FGF2 are well known. 
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Specifically FGF1 and FGF2   induce the promotion  of endothelial  cell 
proliferation and the  physical organization of endothelial  cell proliferation 
and the physical organization of endothelial cells into tube like structures .thus 
they promote angiogenesis FGF1 and FGF2 are more potent  angiogenic factor 
than VEGF or PDGF 
41
.FGF4 also has angiogenic properties
16
 .            
Delivery system for FGF: 
Due to their specific biologic functions and roles, FGF have the 
potential for application to induce the regeneration of a wide spectrum of 
tissuses, including skin, blood vessels, muscle, adipose tendon /ligament, 
cartilage, bone, tooth, and nervous tissuses
46
. Indeed many previous studies 
have evaluated the administration of FGF‟s directly to the sites of wound, 
similar to that of other growth factors. However, when free FGF solutions are 
injected in vivo, they rapidly lose their biological functional activity, primarily 
due to diffusional loss and /or enzymatic inactivation/degradation
48
. Therefore 
gain satisfactory performance, a large amount of FGF‟s with a continuous 
dose for the determined period is required. 
Conversely when FGF‟s   are adsorbed onto or encapsulated within 
materials their degradation risk can be   largely protected  while securing the 
biological activity  .therefore to make full use of the FGF „s  .It is essential to 
develop appropriate  materials and substrates  to contain  and deliver them to 
defective regions  after which following   and substrates to contain and deliver 
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them to defective  regions ,after which allowing their release  at a controllable 
and sustainable rate . A wide range of biomaterials and substrate to contain 
and deliver them defective regions ,after which allowing their release at a 
controllable rate and sustainable rate .A wide range of biomaterials including 
synthetic  and natural polymers and even tissue matrices have been studied as 
candidate materials to carry FGF‟s  and elicit their  therapeutic efficacy in 
vitro nd /or in vivo. 
While their functional activity  has been demonstrated  in different 
types of cells  in vitro and /or target tissues in vivo  there have been relatively 
few ,if any  reports  addressing  the delivery mechanism  .In  this part  ,we 
review  the application  of FGF‟s  in concert  with medical  material for tissue 
regeneration .specific  targets include  skin, cartilage, bone, blood vessel  
muscle, tendon /ligament and nerve.
58
 The materials are developed  to 
specifically  conjugate  with FGF‟s  or encapsulate  with the structure  and are 
engineered  in the form of hydrogels or porous scaffolds    or  nano and 
microparticles. 
Porous scaffolds: 
Generally the most common scaffold  materials range polymers 
(synthetic or natural ) and ceramics to their composites  ,which can be  chosen 
depending  on the tissues of concern .many natural  polymers such as  collagen 
,alginate ,fibrin ,silk, chitosan and GAG‟s  are biologically  well defined, 
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tissue  compatible  and degradable,
8
 therefore they  regarded as feasible   
materials  for the intake of growth factors   within the structures such polymers  
are easily engineered into porous folds by dissolution in water based solutions  
and subsequent freeze drying .because they dissolve   well in water   ,the 
incorporation  of FGF‟s  is possible during the fabrication step17. when  
incorporated  within the structure, growth factor  are released  through the 
scaffold when they  come into contact  with the fluid   .In most cases ,bulk  
diffusion  is the dominant method  of releasing growth factors ,which is led by 
water permeation  and can be accelerated   by collapse of the polymer network   
         Due to their  comprising  a class of proteins  or polysaccharides natural 
polymers contain a large number of  ionic groups ,apart from  chitosan  ,which 
is highly positively charged ,all of other  proteins mentioned  above preserve  
a large number of  negatively charged groups .therefore depending on their 
charge   characteristics   (basic or acidic )  FGFs can form charge –charge  
interactions with natural polymers
54
 .in such cases  the FGF –incorporated 
scaffolds show sustained and long term  delivery of FGF  „s  if their structure 
is maintained without collapse . More specific biochemical interactions 
between the FGF‟s and natural proteins are favoured in maintenance of the 
stability of FGF‟s. 
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FGF in inflammatory conditions 
Michael J cross et al reported that Fibroblast growth factor (FGF) & vascular 
Endothelial Growth factor  (VEGF) can inhibit & deregulate  blood vessel formation  
and causes cancer. FGF and VEGF bind to cell surface receptor with tyrosine kinase 
activity, and activation of receptor kinase activity allows coupling to downstream 
signal transduction pathways that causes proliferation, migration and differentiation 
of endothelial cells. 
Michael Jeffers et al examined the activity of the protein FGF-20 in 2 animal 
models of acute intestinal inflammation and in mechanistic studies in vitro, and 
reported that prophylactic administration of FGF-20 significantly reduced the severity 
and extent of mucosal damage, distal colonic edema, histologic inflammation, and 
epithelial cell loss relative to animals administered vehicle control. No toxicity was 
noted during administration of FGF-20 to normal controls. They concluded that FGF-
20, having demonstrated therapeutic activity in 2 experimental models of intestinal 
inflammation, represents a promising new candidate for the treatment of human 
inflammatory bowel disease. 
Kuo Yuan et al reported that the etiology of pyogenic granuloma was due to 
the imbalance between angiogenesis enhancers like VEGF and bFGF, and inhibitors 
like estrogen receptor, and detected abundant levels of bFGF in the extracellular 
matrix of pyogenic granuloma. 
Lynn K. Chang et al conducted spatio-temporal studies on the growth of 
capillary blood vessels and capillary lymphatic vessels in tissue remodelling, and  
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have suggested that lymphangiogenesis is angiogenesis-dependent. They revisited 
this concept by using fibroblast growth factor 2 (FGF-2) to stimulate the growth of 
both vessel types in the mouse cornea, and demonstrated that there is a dose-
dependent response of FGF-2 for lymphangiogenesis, which can occur in the absence 
of a pre-existing or developing vascular bed, i.e., in the absence of angiogenesis, in 
the mouse cornea. 
Yoshio Shimabukuro et al examined the effect of FGF-2 on the production of 
hyaluronan (HA), an extracellular matrix playing important roles in homeostasis and 
inflammatory/wound healing responses, by human periodontal ligament (HPDL) 
cells. An inhibition binding-protein assay revealed that FGF-2 significantly increased 
HA production by HPDL cells in a dose dependent manner. Their results provided 
new evidence for the possible involvement of FGF-2 in the regulation of HA 
production and its appreciable roles in not only homeostasis but also regeneration of 
periodontal tissues. 
Michele Rossini et al examined the expression of FGF-1 and its receptor 
specifically in various inflammatory renal diseases with interstitial inflammation, 
including lupus nephritis (LN), acute interstitial nephritis (AIN), and acute rejection 
superimposed on CAN, and examined any linkage to type of inflammatory infiltrate 
and fibrosis. They reported that the expression of FGF-1 and FGFR-1 in infiltrating 
lymphocytes and macrophages, and of FGFR-1 in tubules, is supportive, but does not 
prove causality, of the possibility that FGF-1 might have both autocrine and paracrine 
functions in renal inflammation. 
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Sandra I. Zittermann and Andrew C. Issekutz investigated the effect of bFGF 
on acute dermal inflammation and the recruitment of monocytes, T-cells, and 
neutrophils, and reported that bFGF synergistically potentiates inflammatory 
mediator-induced leukocyte recruitment, at least in part, by enhancing CAM up-
regulation on endothelium. 
Young-Suk Kim et al studied the effects of Fibroblast Growth Factor-2 on the 
expression and regulation of chemokines in human dental pulp cells, and suggested 
that FGF-2 plays a role not only as a differentiation inducing factor in the injury 
repair processes of pulpal tissue but also as a positive regulator of chemokine 
expression, which may help in tissue engineering and pulp regeneration using HDPCs 
Jeong Goo Leea et al described the molecular mechanism of endothelial 
mesenchymal transformation (EMT) mediated by fibroblast growth factor-2 (FGF-2) 
in corneal endothelial cells (CECs). They reported that Interleukin-1β (IL-1β) greatly 
upregulates FGF-2 production in CECs, thus leading to FGF-2-mediated EMT. 
Masoomeh et al identified and quantified the marrow stem cells (MSCs) 
derived from blood and bone marrow recruited and migrated to the wound site, and 
showed that the synergistic effects of transforming growth factor-beta (TGF-β) and 
basic fibroblast growth factor (b-FGF) lead to a significant increase in migration and 
recruitment of both PBMSCs and BMSCs to the wound site, with more potent effects 
on PBMSCs as compared with BMSCs. Reverse transcription polymerase chain 
reaction of collagen type I (COL1A1) transcripts (348 bp) confirmed that TGF-β and 
b-FGF activate collagen I (production in marrow stem cells at higher transcription 
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levels), with more vigorous effects of TGF-β on PBMSCs as compared with the same 
condition on BMSCs. 
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MATERIALS AND METHODS 
A total of 52 subjects were included in the study based on the 
following criteria: 
INCLUSION CRITERIA: 
  52 Patients who reported to the department of periodontology at Ragas 
dental college and hospital, Uthandi, Chennai were divided into 2 groups  
according to the 1999 AAP  criteria based on their  periodontal status  
1. GROUP A: 
Chronic periodontitis and tobacco chewers -27 systemically healthy  
subjects between  20-60 years  of age with Chronic periodontitis  and 
who consume tobacco  in forms of Pan masala, Gutka, Hans and  Snuff 
products  etc  for the past 6 months  and above diagnosis of generalized 
chronic periodontitis was made based on Clinical parameters of PPD 
>/5mm ,CAL>/3mm  in > 30  sites . 
2. GROUP B : 
Periodontally healthy patients -25  systemically healthy subjects 
between  20 -60 years  of age  with periodontal health. Periodontal 
Health  was determined by absence of bleeding on probing,                       
PPD <3mm and no evidence of clinical attachment loss. 
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Subjects who could fulfill the Scheduled appointment and who could give 
written informed consent will be included in the study. In addition the patients 
should exhibit a Normal salivary flow rate of at least >/0.5ml/min following 
a 5 minute salivary flow rate.   
 The study was undertaken following approval from the institutional 
review board. All the subjects were informed that this research work was in no 
way directly related to the therapy or cure of the disease. Informed consent 
was obtained from the subjects who accepted to participate in the study. 
EXCLUSION CRITERIA: 
 Patients with any systemic diseases that influence salivary gland 
behaviour. 
 Patients who are under any medications that affect salivary flow. 
 Pregnant women and lactating mothers. 
 Patients with OSMF or any other mucosal lesions that relate to tobacco 
chewing  
METHOD: 
PERIODONTAL EXAMINATION: 
              Subjects enrolled in the study were examined with a mouth mirror 
and Williams Periodontal probe. Clinical  diagnosis  of generalized  chronic  
periodontitis  was based on measurements of Pocket probing depth, Clinical 
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attachment  loss , Gingival bleeding Index  (Full mouth  gingival  bleeding  
score  FMBS), Plaque Index (full mouth  Plaque score –FMPS), Full mouth 
plaque and bleeding scores were recorded by examining four  surfaces per 
Tooth : Labial/buccal, lingual/Palatal, mesial and distal  surfaces.  
Saliva Collection: 
The technique proposed by Navazesh et al. (2008) was used for saliva 
collection. 5ml of unstimulated saliva was collected in a sterile disposable 
plastic container. The subjects were asked to refrain from intake of any food or 
beverage (except water) one hour before the test session. They were advised to 
rinse their mouth several times with plain water and to relax for five minutes 
before sample collection. The subjects were then asked to lean the head 
forward over the container with the mouth slightly open and allow the saliva 
to drain into the container with eyes open. The time given for saliva sample 
collection was 5-10 minutes. The saliva samples were centrifuged at 2800rpm 
and stored at -20 degree Celsius till further analysis was done. 
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ARMAMENTARIUM  
DIAGNOSTIC INSTRUMENTS 
1. Mouth mirrors 
2. Graduated William’s probe. 
3. Tweezers 
ARMAMENTARIUM - II: 
1. Vaccutainers (clot activator) 
2. Disposable containers for saliva collection, 
3. Centrifuge tubes, 
4. Laboratory Centrifuge 
5. Eppendorf tubes, 
6. Ice pack (for transfer) 
7. Refrigerator (-21), 
8. adjustable single channel micropipettes 
9. disposable tips for use with single channel micropipettes 
10. Microtitre plate reader 
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11. Microplate washer, 
12. Centrifuge 
13. Immunoassay analyzer 
14. Distilled water, 
15. Miscellaneous laboratory items 
i. Beaker 
ii. Tissue paper 
iii. Gloves 
iv. Tin foil 
16. Sandwich ELISA kits 
a. Human bFGF Kit: Ray Biotech which contains 
1. bFGF-A Microplate (A)    
2. Wash Buffer Concentrate (20X) (B)  
3. Standard Protein (C) 
4. Detection Antibody bFGF (F) 
5. HRP-Streptavidin Concentrate (G) 
6. TMB- One step substrate Reagent ( H) 
7. Stop Solution ( I) 
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8. Sample diluent buffer(D2) 
9. Assay Diluent B (E2) 
10. cell lysate buffer (J) 
 Additional Materials Required: 
1. Microplate reader capable of measuring absorbance at  
450nm. 
2. Precision pipettes to deliver 2ul to 1 ml volumes. 
3. Adjustable 1-25ml pipettes for reagent preparation 
4. 100ml and 1 liter graduated cylinders 
5. Absorbent paper. 
6. Distilled or deionized water 
7. Log-log graph paper or computer and software for ELISA  
                           data analysis 
8. Tubes to prepare standard or sample dilutions. 
REAGENT PREPARATION: 
1. Reagents and samples were brought to room temperature (18-25’C) 
before using the sample diluent Buffer (D2) and assay diluent (E2) were 
diluted 5-fold with deionized or distilled water before use. cell lysate 
buffer (J) was diluted 2-fold with deionised or distilled water 
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2. Sample Dilution: tissue lysate and cell lysate was diluted atleast 5 fold 
with 1X sample diluent buffer (D2). as recommend a minimum of 1mg 
of protein per 1ml of original lysate solution standard protein (C) vial 
3. To prepare a100ng/ml standard. Dissolve the powder thoroughly by a 
gentle mix. Add100μl bFGF standard from the vial of standard protein 
(C), into a tube with 900μl sample Diluent buffer to prepare a 10000 
pg/ml standard solution. Pipette 300μl 1X sample 
4. Diluent Buffer was eluted into each tube and the stock standard solution 
was as per manufacturer’s instructions. 
5. 100ul of 1X Assay Diluent was added into the vial to prepare a detection 
antibody concentrate, Pipetted up and down and mixed gently. 
6. The detection antibody concentrate WAS diluted 5 fold with 1X Assay 
Diluent (E2) before use. 
7. HRP-Streptavidin concentrate was diluted 120-fold  with 1X Assay 
Diluent 
ASSAY PROCEDURE: 
  Samples were brought to room temperature and all reagents 
were prepared according to manufacturer’s instructions. 
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S.No ASSAY 
STEPS 
PROCEDURE 
1 Addition A serial dilution of the stock standard was prepared to 
obtain a standard curve 
2 Addition 100µl of each, sample and zero, was added in 
appropriate number of wells 
3 Incubation The wells were covered with the plastic cover plate 
and incubated at room temperature for 2 hours 
4 Wash The cover was removed and wells washed as follows 
a. Aspiration of contents from each well 
b. Addition of 0.3ml of 1x wash buffer into each 
well 
c. Aspiration of the contents again 
d. Repetition of steps b and c 2 more times 
5 Addition 50µl of diluted biotinylated anti-IL-17A was added to 
all wells 
6 Incubation Wells were covered with plastic plate cover and 
incubated at room temperature for 1 hour 
7 Wash Step 4 was repeated 
8 Addition 100µl of Streptavidin-HRP solution was added to all 
wells 
9 Incubation Wells were covered with plastic plate cover and 
incubated at room temperature for 30 mins 
10 Wash Step 4 was repeated 
11 Addition 100µl of TMB substrate solution was added to all 
wells 
12 Incubation Wells were covered with plastic plate cover and 
incubated at room temperature in the dark for 15 mins 
13 Addition 100µl of stop reagent was added to all wells 
 The micro plate reader was used at 450nm to read the absorbance value 
in each well and quantify the bFGF levels. 
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STATISTICAL ANALYSIS: 
The mean values of  bFGF in both test and control groups were used 
for analysis. Both paired t test and the Mann Whitney U test were used to 
compare the health versus disease results and significance was set at p<0.05. 
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PROFORMA 
Evaluation of salivary basic fibroblast growth factor (bFGF) 
levels in tobacco chewers with chronic periodontitis  
CASE NO:                A/B                                                                   DATE: 
NAME:                                                                            
AGE: 
SEX: 
CHIEF COMPLAINT: 
 
PAST MEDICAL HISTORY: 
 
PAST DENTAL HISTORY: 
 
PERSONAL HISTORY: 
ORAL HYGIENE STATUS: 
 
 
TOBACCO USAGE:                                        SMOKING/NON –SMOKING 
DURATION: 
FREQUENCY: 
TYPE: 
IT USED IN COMBINATION: 
ALCOHOL USE:               YES/NO 
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INTRA-ORAL SOFT TISSUE EXAMINATION 
BUCCAL MUCOSA: 
TONGUE: 
PALATE: 
ALVEOLAR MUCOSA: 
GINIGIVAL EXAMINATION 
PHENOTYPE: 
 
PIGMENTATION: 
 
CONSISTENCY: 
 
RADOIGRAPHIC FINDINGS 
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Consent Form 
I……………………………….S/o,d/o,w/o…………………………………….
.agedabout………………………..years……………………….residing 
at………………………………………………do solemnly 
And state as follows. 
I have been explained about the nature and purpose of the study in which I 
have been asked to participate. 
I give my consent after knowing full consequence of the 
dissertation/thesis/study and I undertake to cooperate with the doctor for the 
study. 
I have been given the opportunity to ask questions about the procedure. 
I also authorize the Doctor to proceed with the study and I will cooperate with 
the doctor. 
I have also agreed to come for regular follow up for a period of atleast one 
year. 
I am also aware that I am free to withdraw the consent given at any time 
during the study in writing. 
The doctor has explained the procedure to me and I have understood the 
same and signed my consent in 
(English/Tamil/Hindi/Telugu.............................). 
SIGNATURE OF THE PG STUDENT                                  SIGNATURE OF THE PATIENT 
 
  SIGNATURE OF THE GUIDE:                              SIGNATURE OF THE HOD 
 
Counselling Form: 
Tobacco usage……………………….. packets per year 
I was advised regarding ill effects of tobacco use and motivated for tobacco 
cessation.  
SIGNATURE OF THE PG STUDENT                                           SIGNATURE OF THE PATIENT 
                          
 
 
 
 
 
Photographs  
 
Photographs 
 
FIG .1.   DISPOSABLE SALIVA CONTAINERS 
 
 
 
FIG.2. EPPENDORF TUBES 
 
 
 
 
 
 
Photographs 
 
FIG .3. SAMPLE COLLECTION 
 
 
FIG.4. CENTRIFUGE 
 
 
 
Photographs 
 
 
FIG.5. MICRO PIPETTE AND TIPS 
 
 
FIG.6 AUTO WASHER 
 
 
 
 
 
 
Photographs 
 
FIG. 7 .MICRO PLATE READER 
 
 
 
 
 
FIG.8 REFRIGERATOR 
 
 
 
 
 
 
Photographs 
 
FIG.9.COMPUTER 
 
 
FIG 10 IMMUNOANALYZER 
 
 
 
 
 
 
 
 
Photographs 
 
PROCEDURE 
FIG 11 MICROPLATE WELL DURING PROCEDURE 
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FIG 13 RESULTS PRINTED OUT BY THE IMMUNO ASSAY 
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RESULTS 
The study is aimed at comparison of bFGF in saliva of subjects with 
chronic periodontitis and those with periodontal health. 
27 patients with chronic periodontitis associated with tobacco chewing 
and 25 healthy subjects were included in the study. Saliva samples were 
collected from each group. FGF levels in saliva were assessed using sandwich 
ELISA technique. 
Saliva was collected in sputum container and stored in refrigerator at 
25˚C. Fibroblast Growth Factor levels were assessed using sandwich ELISA 
technique. Absorbance was measured at 450 nm as primary wavelength and as 
reference wavelength in terms of 650 nm. 
The raw data from all the samples examined are represented in table 1 
and table 2. 
The ELISA results followed the standard curve, indicating the 
reproducibility and the accuracy of the results obtained. The standard curve in 
represented in . 
The mean concentration of bFGF in chronic periodontitis patients with 
tobacco chewing habit is 329.012 +/ 178.643 pg, while that of healthy persons 
is 92.261 pg. There is a statistically significant difference between the disease 
and health samples at p<0.000. 
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Intergroup comparison of calculated concentration in tobacco chewers 
with chronic periodontitis and healthy persons using Mann –Whitney U 
test: 
 When the Mann Whitney U test was used there was a statistically 
significant increase (p<0.000) of  bFGF in chronic periodontititis patients  
when compared to  healthy group . 
These results are represented in table 5. 
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Table : 1 
 
   Saliva samples 
Sample No 
Name of the 
patient 
Absorbance 
Calculated 
concentration (pg/ml) 
  Tobacco chewers with chronic periodontitis 
1 T1 0.084 237.367 
2 T2 0.102 401.019 
3 T3 0.092 310.101 
4 T4 0.088 273.734 
5 T5 0.098 364.652 
6 T6 0.072 128.265 
7 T7 0.123 591.947 
8 T8 0.099 373.744 
9 T9 0.080 201.000 
10 T10 0.140 746.507 
11 T11 0.069 100.990 
12 T12 0.101 391.927 
13 T13 0.071 119.173 
14 T14 0.118 546.488 
15 T15 0.077 173.724 
16 T16 0.085 246.459 
17 T17 0.125 610.130 
18 T18 0.091 301.009 
19 T19 0.071 119.173 
20 T20 0.072 128.265 
21 T21 0.082 219.183 
22 T22 0.105 428.294 
23 T23 0.125 610.130 
24 T24 0.089 282.826 
25 T25 0.093 319.193 
26 T26 0.070 110.082 
27 T27 0.108 455.570 
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Healthy subjects 
1 H1 0.083 228.275 
2 H2 0.081 210.091 
3 H3 0.064 55.531 
4 H4 0.065 64.623 
5 H5 0.069 100.990 
6 H6 0.076 164.632 
7 H7 0.074 146.449 
8 H8 0.062 37.347 
9 H9 0.066 73.714 
10 H10 0.065 64.623 
11 H11 0.061 28.256 
12 H12 0.062 37.347 
13 H13 0.065 64.623 
14 H14 0.074 146.449 
15 H15 0.061 28.256 
16 H16 0.065 64.623 
17 H17 0.068 91.898 
18 H18 0.060 19.164 
19 H19 0.065 64.623 
20 H20 0.067 82.806 
21 H21 0.065 64.623 
22 H22 0.086 255.550 
23 H23 0.066 73.714 
24 H24 0.069 100.990 
25 H25 0.062 37.347 
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Table : 3 
  
STANDARD CURVE 
  
      
Standard reading 
 
  
Standards Absorbance 
102.4 0.074 
256 0.103 
640 0.128 
1600 0.208 
4000 0.499 
10000 1.161 
  
  
  
  
  
  
  
  
  
R2 = 0.9989 
    
  
slope= 0.0001 
 
 
  
  
intercept= 0.0579 
    
        
  
Blank 0.051 
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DISCUSSION 
Periodontitis is a chronic inflammatory disease that is initiated as 
gingival inflammation in response to plaque microorganisms. The exact 
mechanisms for the transition from gingivitis to periodontitis are not yet 
known but individual disease susceptibility seems to play a major role.
111
  The 
various factors that affect disease susceptibility include genetic and 
environmental factors.
75
  
Environmental factors such as lifestyle dietary habits and tobacco 
related habits.
37
  There is voluminous literature linking smoking increased 
severity of periodontal diseases, worsening of prognosis and delayed wound 
healing. Tobacco chewing is an habit that is prevalent in certain cultures of 
Asian subcontinent, including India.
2
 Although not as well documented as 
smoking the effects of tobacco chewing on the oral cavity and the 
periodontium is also well recognised.
35
 
 Existing literature has reported a variety of oral lesions such as 
mucosal lesions, premalignant lesions like leukoplakia and malignancies like 
Squamous cell carcinoma, to be associated with tobacco chewing habit
66
. In 
relation to the periodontium, the most commonly reported symptoms include 
burning sensation in the gingiva, halitosis, ulcerations in the oral cavity and 
gingiva and discolouration of teeth
76
.   
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 Previous literature has reported that in spite of no significant 
difference between quid chewers and non chewers with respect to oral 
hygiene, there was a greater severity of periodontal disease.
5
       
CPI-code -4 with a probing depth of > 6mm was seen in 30% of pan 
chewers in tobacco compared with 7.3% of pan chewers without tobacco. It 
was found  that Pan chewers  with tobacco had 4.7  times  more risk of having  
periodontal pockets than Pan chewrs without tobacco.
30
  
Smokeless tobacco users tend to have more severe REC  and CAL and 
a greater proportion of site  with higher values of  REC and CAL compared 
with never users
6
. The greatest increase in severity of CAL was found to be 
localised to sites  on mandibular ,anterior teeth and molar which may be the 
result of retention of the smokeless tobacco (ST)  product in the oral cavity. 
The present study was undertaken with the aim to obtain a better 
understanding of   the etiopathogenic mechanisms underlying the periodontal 
diseases that is associated with tobacco chewing habit. 
In the present study only patients who exhibited Tobacco chewing 
habit (Pan chewers) were included. Patients with concomitant tobacco 
smoking habit were excluded from the study to avoid counfounding of the 
results.  Patients included in the study exhibited clinical signs of periodontitis 
but no other   mucosal / malignant or premalignant lesions. This   was done to 
ensure that the marker used in the study (bFGF) would show changes relating 
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only to Periodontal inflammation and not due to any other inflammation/ 
malignancy in the oral cavity. Previous studies have documented increased 
bFGF presence in saliva in patients with oral malignancy
36
.  
   The pathogenic mechanisms underlying the disease process had been 
documented. Arecoline the major alkaloid of arecanut , inhibit cell attachment 
cell spreading  and cell migration and decreased  cell growth and  collagen 
synthesis. Arecanut  extract induce the production of PGE2,
59
 the activation of 
intracellular calcium, concentrate P-38 mitogen activated protein kinase 
62
 and 
the extracellular  signal regulated  protein kinase inhibitor. All these findings 
suggest that areca nut chewing may induce an inflammatory response
117
.         
Fibroblast growth factor is a multipotent growth factor  that produces  
different effects  depending on the cell types it acts
7
. b Fibroblast  growth 
factor is thought  is thought  to be the most biologically active  among this 
family of proteins. It is a potent angiogenic factor
19
 and it also involved in 
collagen synthesis
18
 and matrix turnover by the fibroblast
39
. As both 
neovascularisation and fibrosis are commonly associated with tobacco 
chewers, bFGF   may be implicated in the pathogenesis of periodontal disease 
that is associated with tobacco chewing habit 
12
. 
  The present study was undertaken to investigate if FGF levels were 
altered in periodontal disease when compared to health. 
Saliva was chosen as the medium because of the following reasons  
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1. Ease of collection, non invasiveness and rapid screening  
2. Pan chewing habit  has been linked with  pathologically  changes in 
the oral cavity as a whole without any direct influence on the salivary glands,  
making saliva a  more suitable candidate when compared to GCF . 
The ELISA method was chosen for the estimation of FGF because of 
its predictability and reproducibility of results.
43
 The other methods of protein 
estimation such as NMR tend to be much more extensive in nature and the 
clinical applicability of these techniques is somewhat limited by their cost. 
PCR dependent methods although more accurate, estimate only the mRNA in 
a given sample and may not give a complete representation of the functional 
protein available
55
. 
The results of the study indicate that there was a significantly higher 
expression of bFGF in the test group when compared to the controls  
Due to the previous explained exclusion criteria, it can be hypothetised  
that the significantly higher salivary  bFGF  values related to periodontal 
disease. 
These results are in agreement with the results of Kuo Yuan et al who 
studied FGF levels in in gingiva of chronic periodontitis sample. 
As salivary bFGF levels are obtained from tissue, it can be 
fypothesized that our results are in agreement with these results. 
Discussion 
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There are no previous results of bFGF in periodontal disease with 
which these results can be compared. However, Yuan et al, have studied the 
role of bFGF in pyogenic granuloma and have reported increased expression 
of FGF in the inflammatory/ angiogenic lesion.  
Nicotine and arecoline present in pan are known to significantly affect 
vascularity and increase inflammation.  
bFGF levels may be upregulated through the following mechanisms 
1. Nicotine may directly induce upregulation of bFGF through its 
effect on neovascularisation as it is absorbed through the mucosal 
tissues. 
2. Nicotine, nitrosamine, arecholine induce inflammatory changes by 
upregulation of pro inflammatory mediators such as IL-1. IL6 and 
PGE2. These mediators in turn, affect angiogenesis through its 
effects on the angioblasts, thereby indirectly upregulating Bfgf 
It is possible that the greater bFGF presence in saliva is a result of the 
increased vascular tissue response to these agents. 
Additionally, the role of pan in inducing fibrosis is well established. 
The results of this study indicate that the increase in FGF is related to the 
fibrotic changes that occur in the oral cavity as a whole including the 
periodontium. 
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Nicotine and other products are absorbed through the oral mucosa and 
thereby gain access to the fibroblasts of the oral cavity, including the gingival 
fibroblasts.
83 
 On stimulation, directly by the areca nut products or indirectly 
through inflammatory mediators, fibroblasts produce increased levels of 
bFGF, the primary response being matrix turnover. 
These changes have been previously reported by Robertson et al. and our 
results only reinforce the above results. 
 Saliva is a second hand marker in periodontal disease, all its 
constituents are probably released from the GCF. In turn, GCF is thought to 
reflect the environment of the periodontal tissues that it is closely associated 
with. 
The clinical implications of the study are as follows: 
1. FGF may be used as a marker for predicting progression of 
periodontal disease in tobacco chewers. Long term studies with a 
greater sample size could help establish its reliability as a marker. 
2. FGF or its signalling pathways may be used as a therapeutic target 
to treat fibrotic changes that occur as a result of tobacco chewing. 
Further studies are required to elucidate the molecular mechanisms 
that regulate the process. 
3. FGF has already been used for regenerative therapy in animal 
models for furcation defects; its use has been approved for human 
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use as well. These results suggest that one must excise caution in 
using FGF for regenerative purpose in tobacco chewers because of 
its strong association with fibrosis as fibrosis in itself may be 
detrimental to periodontal regeneration. 
This study has the following limitations: 
1. The sample size is reasonably small considering the population and the 
prevalence of tobacco use. Therefore the power of the study is not 
high.   
2. The cross-sectional nature of the study means that the progression of 
the disease is not determined which would require longitudinal studies.        
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SUMMARY AND CONCLUSION 
           The study titled “Evaluation of salivary basic Fibroblast Growth Factor 
(bFGF) in tobacco chewers with chronic periodontitis” using sandwich ELISA 
technique enrolled fifty-two patients seeking periodontal treatment with tobacco 
usage assessed as using any form of smokeless tobacco for a period of least                     
6 months. 
 After oral prophylaxis, unstimulated pooled saliva was collected as per 
established protocol. The     technique    proposed    by     Navazesh     et    al 
(2008) was used for saliva collection.   5ml   of  unstimulated   saliva  was    
collected  in  a sterile container, by asking the subjects  to  lean  the  head  
forward  over  the  container with the mouth slightly open and allow the saliva to 
drain into the container. The time given for saliva sample collection was 5-10 
minutes. The saliva samples were centrifuged at 2800 rpm and stored at -20 
degree Celsius, and results were statistically analyzed. 
Within the limits of this study, the following conclusions have been 
elucidated: 
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The patients who consume tobacco showed higher salivary bFGF (329.012 
+/ 178.643 pg) in chronic periodontitis than healthy patients (92.261 pg) with 
p<0.000, suggesting that bFGF may play an important role in the disease 
pathogenesis and progression.  
However, further controlled clinical trials with a larger sample size should 
be executed to evaluate the effectiveness of this marker. 
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